Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer

This study has been withdrawn prior to enrollment.
(poor enrollment)
Information provided by:
Samsung Medical Center Identifier:
First received: May 22, 2006
Last updated: August 26, 2010
Last verified: July 2010

This study is randomized phase III trial designed to assess whether (preoperative) neoadjuvant chemotherapy followed by surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (experimental treatment) improves 3-year disease-free survival, compared to surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (standard treatment) in stage IB, IIA, IIB and T3N1 non-small cell lung cancer

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: gemcitabine, cisplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Plus Adjuvant Chemotherapy Versus Surgery Plus Adjuvant Chemotherapy in Stage IB, IIA, IIB and T3N1 Non-small Cell Lung Cancer (ICON)

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • 3-year disease-free survival

Secondary Outcome Measures:
  • overall survival
  • pattern of relapse
  • quality of life
  • operative mortality and toxicity

Enrollment: 0
Study Start Date: April 2006
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gem/Cis
neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
Drug: gemcitabine, cisplatin
No Intervention: no neoadjuvant chemotherapy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven NSCLC patients
  • All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest CT and PET-CT
  • 18 year of ages or older
  • ECOG performance status 0-1
  • Uni-dimensionally measurable lesion by RECIST criteria
  • No prior chemotherapy or radiotherapy for NSCLC
  • Pre-operative FEV1 ≥ 2.0 L evaluated within 28 days
  • Adequate bone marrow function: Hb > 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥ 100,000/μL
  • Adequate liver and renal function: Total bilirubin < 2 x ULN, AST/ALT < 3 x ULN, serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min
  • Written informed consent

Exclusion Criteria:

  • Superior sulcus tumor
  • Prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years
  • Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia
  • Recent myocardial infarction within 6 months
  • Patients with post-obstructive pneumonia or serious infection
  • Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method.)
  • Patients with psychological problem
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00329472

Sponsors and Collaborators
Samsung Medical Center
Principal Investigator: Keunchil Park, M.D. Samsung Medical Center
  More Information

No publications provided

Responsible Party: Keunchil Park/Professor, Samsung Medical Center Identifier: NCT00329472     History of Changes
Other Study ID Numbers: 2004-09-027
Study First Received: May 22, 2006
Last Updated: August 26, 2010
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on February 25, 2015